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 Despite declining incidence and mortality, gastric cancer remains the fourth 
most common cancer and the second leading cause of death in the world. Gastric 
carcinogenesis is believed to occur through one of 3 pathways, the commonest of 
which involves sequential changes in mucosal histology, from normal through 
intestinal metaplasia and dysplasia to overt carcinoma. We aimed to investigate the 
genomic changes that parallel these mucosal transformations as they progress along 
the pathway described by Correa in 1988. 
 57 specimens representing the histological types of overt carcinoma, dysplasia, 
intestinal metaplasia and adjacent histologically normal mucosa were obtained from 
the archived formalin-fixed paraffin-embedded pathology blocks of 17 patients. 
Genomic DNA was extracted from each specimen. Comparative genomic 
hybridization was performed using a validated 2464-BAC clone array having an 
average inter-clone interval of 1.4 Mb.  
 Our results revealed that all 4 histological types harbored extensive genomic 
changes that were highly similar. Further array CGH experiments conducted with 
tissue harvested from non-cancer gastrectomy specimens showed no evidence of 
significant copy number aberrations. Additional experiments found that the distant 
margin blocks of the same cancer patients had a distinctly different genomic signature 
compared to the earlier 57 specimens. 
 Several prospective sets of specimens that were harvested and processed in our 
laboratory confirmed that the genomic profile of gastric mucosa at the margin of a 
cancer resection is almost normal while the copy number aberrations in adjacent 
histologically normal gastric mucosa mirror those found in the tumor itself. 
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 Several regions of interest that were found in our study included the +20q13, 
+8z23, -19p13 and +17q21 cytobands. These copy number aberrations were present in 
the adjacent mucosa as well as in the tumors. 
 The genome-wide study of adjacent normal mucosa in gastric cancer with 
array CGH has not been reported before and our findings are consistent with and 
provide genomic evidence for field cancerization in gastric adenocarcinoma. Our 
findings in gastric carcinoma are supported by recent discoveries of genomic, 
proteomic and nanoscale structural abnormalities in histologically normal adjacent 
colonic, prostatic, pancreatic and pulmonary tissue from cancer patients.  
The concept of field cancerization was first proposed in 1953. This theory 
suggests that chronic exposure to a DNA-damaging agent such as a chemical 
compound or an infection like H.pylori leads to the clonal expansion of inappropriate 
cell types that exhibit genetic instability. This premalignant state would eventually 
lead to transformation into overt carcinoma. The field cancerization theory mirrors the 
Correa hypothesis and it provides some explanation for the frequency of recurrence in 
gastric cancer patients.  
The understanding of gastric carcinogenesis as a field cancerization event 
would provide the impetus to focus resources on the study of premalignant 
histologically normal gastric mucosa that harbors the initiators of gastric 
carcinogenesis. 
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Introduction and Literature Review 
 
1.1 Gastric cancer epidemiology  
 Despite a major decline in incidence and mortality rates over the last fifty 
years, gastric cancer remains the fourth most common cancer and the second leading 
cause of cancer death in the world (1). More recently, developing countries have 
tended to predominate in incidence. Changes in diet and improvements in hygiene are 
generally considered as being responsible for the decrease in incidence rates in the 
developed world (2). Male-to-female incidence ratios are usually about 1.5 to 2.5 with 
higher ratios for intestinal-type cancer and higher risk populations (3). 
 The incidence of gastric cancer in Singapore has likewise been decreasing. 
However, it remains firmly within the top five malignancies in the country. The latest 
census shows that it is the 4th most common malignancy and the 3rd greatest cause of 
cancer-related mortality in both males and females combined (4). 
 Most cases of gastric cancer present at an advanced stage and this is reflected 
in the fact that the mortality rate of gastric cancer in a population is usually higher 
than its incidence rate. The possible exceptions to this are countries with a high 
incidence which have developed mass screening programs. Identifying and treating 
gastric cancer at an early stage has the effect of prolonging overall survival and this 
has been observed in Japan in the last 15 years.  
The Singapore Gastric Cancer Epidemiology and Molecular Genetics Program 
(GCEP) established in 2003 involves active mass screening of a cohort of 4000 
patients in an attempt to determine possible targets for primary or secondary 
prevention in order to reduce the incidence of gastric carcinoma (5). 
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1.2 Gastric cancer pathology 
 It is generally recognized that there are 2 main histological types of gastric 
carcinoma as first described in 1965 (6). The Lauren classification defines these as: (a) 
the intestinal type which is characterized by the metaplastic transformation of gastric-
type mucosa to an intestinal type with abundant goblet cells; and, (b) the diffuse type 
which is defined by the presence of poorly differentiated signet ring cells. Both types 




Figure 1. Histology of gastric mucosa 
Normal gastric epithelium 




 The intestinal type is the more common variant seen and it is associated with 
an increased incidence of chronic atrophic gastritis and gastric atrophy. The diffuse 
cancers do not have this association. It is believed that intestinal metaplasia (IM) is the 
result of an inflammatory reaction which may be precipitated by ingestion of certain 
substances or by the presence of an infection such as Helicobacter pylori.  
 The occurrence of gastric dysplasia has been postulated to be a further step in 
the development of intestinal-type gastric cancer (7) although it is known that it may 
on occasion regress. The problems associated with histological interpretation of 
dysplasia are well-documented and these include inter-observational variation as well 
as the difficulty in differentiating high-grade dysplasia from intramucosal carcinoma 
(also known as early gastric cancer). The Vienna classification (8) (9) now provides 
for more accurate diagnosis of dysplastic lesions. Nevertheless, the difficulty of 
diagnosing dsyplasia accurately has hindered studies involving DNA or RNA as fresh 
frozen specimens cannot be read with the required degree of accuracy while formalin-
fixed paraffin-embedded tissue is usually of suboptimal quality for genetic assays. 
 The other important category of precancerous stomach lesions are gastric 
mucosal polyps. These may be divided into 3 main categories: fundic gland polyps; 
hyperplastic polyps, and adenomas. The latter 2 have a slightly increased risk of 
progressing to carcinoma, with adenomas generally recognized as being of greater 
significance. 
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1.3 Etiology & Risk Factors  
 
1.3.1 Risk Factors 
 With the exception of genetic syndromes, by far the strongest established risk 
factor for gastric cancer is H. pylori infection. Male gender, smoking, previous gastric 
resections and adenomatous polyps have also been associated with a higher incidence 
of gastric carcinoma. Epstein-Barr virus has also been reported to be responsible for 
approximately 5% of stomach malignancies and this subtype of gastric cancer has 
















       Table 1. Risk factors for gastric cancer 
Infection: Helicobacter pylori 
  Epstein-Barr virus 
Atrophic gastritis 
Previous partial gastrectomy 
Adenomatous gastric polyps 
Blood group A 
Type III intestinal metaplasia 
Smoking 
High salt intake and/or preserved foods 
Genetic: Familial adenomatous polyposis (FAP) 
  Hereditary diffuse gastric cancer (HDGC) 
  Peutz-Jeghers Syndrome 
  Hereditary Nonpolyposis Colon Cancer (HNPCC) 





 It has been postulated that there are at least 3 important pathways that lead to 
cancer in the stomach: (a) stepwise morphological transformation involving intestinal 
metaplasia; (b) diffuse type gastric carcinoma which involves signet ring cells thought 
to arise from the stem cell zone; and , (c) spasmolytic polypeptide expressing 
metaplasia (SPEM) where the gastric glands become filled with cells that express the 
polypeptide TFF2 (TreFoil Factor-2 also known as SP)  (11). 
 The fundamental mechanisms underlying these pathways generally involve 
some degree of genomic instability. Several phenotypes of instability have been 
identified in gastric cancer (12).  
The chromosomal instability phenotype is associated with mutation in genes 
that control the segregation of genetic elements. Chromosomal rearrangement or 
losses or gains of chromosomes can lead to either oncogene activation or tumor-
suppressor gene inactivation. 
The microsatellite instability (MSI) phenotype is characterized by defective 
repair of DNA replication. Inefficiencies of one or more of the mismatch repair genes 
can cause MSI which then results in frameshift mutations, thus altering the translation 
of DNA into protein products. 
The third phenotype involves the cytosine p guanine (CpG) island methylator. 
Abnormal methylation of guanine and cytosine-rich regions results in silencing of 
tumor-suppressor genes leading to uncontrolled cellular growth and malignancy. 
 The recent discovery of cancer stem cells has led to the intriguing possibility 
that these immortal cells may be a key initiator of gastric carcinogenesis (13) (14). 
The stem cell may either be an organ-specific indigenous gastric stem cell or a bone 
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marrow-derived cell (BMDC) recruited to the gastric epithelium as a result of chronic 
inflammatory stress. 
 
1.3.3 Hereditary diffuse gastric cancer (HGDC) 
 
 Diffuse-type gastric carcinoma is distinguished by the absence of defined 
premalignant lesions and poorly differentiated histology (6). It is also associated with 
H. pylori infection and is sometimes described as ‘linitis plastica’ alluding to a 
macroscopic appearance of widespread thickening involving the entire organ.  
 The discovery of the genetic events leading to diffuse gastric carcinoma is one 
of the success stories of modern genomics. A kindred of New Zealand Maoris that had 
diffuse-type carcinoma were found to have hereditary mutations of CDH1, a tumor-
suppressor gene which codes for the protein E-cadherin (15). This protein mediates 
homophilic cell-cell interactions and establishes cell polarity. Loss of both alleles of 
the gene results in reduced expression of cadherin and this is found in up to 50% of all 
gastric cancers and up to 83% of diffuse carcinomas (16). 
 
1.3.4 Correa’s hypothesis  
 
 Also known as the intestinal pathway of gastric carcinogenesis, this hypothesis 
is central to our study as intestinal-type carcinoma is the predominant form in our 
population. Pelayo Correa first postulated in 1975 that nitroso compounds arising 
from ingested nitrites, in the presence of an impaired mucous barrier, may be the 
initiating step in a cascade of events leading to overt carcinoma (17).  
 7 
 
Figure 2.Correa’s hypothesis of gastric cancer etiology (7)
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 The Correa model of gastric carcinogenesis implicates four distinct 
histological entities: normal mucosa, intestinal metaplasia, dysplasia and carcinoma. 
Assuming that accurate samples are obtained, it would then be possible to elucidate 
the molecular and genomic signatures of each histological type. The accumulation of 
genetic alterations in a linear or parallel route to overt carcinoma may then be 
described much as it already has in colorectal malignancies (18). 
 
1.4 Screening for Gastric adenocarcinoma 
 
 A mass screening program for gastric cancer has existed in Japan since 1960 
(19). Despite intensive research for the last 49 years, the only recommended tools for 
screening today remain diagnostic contrast radiography and endoscopy. 
The last 20 years has seen rapid advances in technology for biomedical 
research. The search for biomarkers is particularly interesting as it may one day 
provide a simple tool for mass screening of any number of diseases, gastric cancer 
among them. The advantages of a biomarker cannot be overstated as the cost of any 
blood test or genetic test would almost certainly be at least an order of magnitude less 
than that of endoscopy. The convenience of a serum biomarker would also encourage 
a population to come forward for screening. 
 Biomarker discovery and genetic research are inextricably linked. A biomarker 
may be a protein or even a genetic test itself. Thus one possible avenue for biomarker 
discovery would lie along the route of research into abnormalities in the genomic 
DNA of cancer patients. 
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1.5 Management of gastric cancer 
 
 The diagnosis of gastric cancer is in almost all instances made on diagnostic 
endoscopy and biopsy. This is an invasive procedure and relatively expensive. As 
early gastric cancer may be asymptomatic or present with non-specific symptoms such 
as dyspepsia, the majority of patients are usually diagnosed at stage II or worse unless 
there is a nationwide screening program in place. 
 Surgical removal of the primary tumor and regional lymph nodes is the only 
curative option for gastric cancer. Adjuvant chemotherapy and radiotherapy provide 
adjuncts to curative surgery and also serve to slow tumor progression in advanced 
cases. Neoadjuvant therapy may reduce tumor volume with the goal of eventual 
curative resection. 
 Staging of the disease prior to surgery and at follow-up after surgery is usually 
with CT scans and endoscopy. The problem with this is that microscopic disease is not 
detectable with these methods and when macroscopic recurrence occurs it usually 
signifies metastatic or incurable disease. Thus the issue of recurrence, particularly in 
the locoregional lymph nodes, at the resection site and on peritoneal surfaces, 
constitutes a difficult diagnostic and treatment problem. 
 In general, 5-year survival rates for gastric cancer are approximately 20% 
worldwide except in Japan where the mass screening program and aggressive early 
treatment has contributed to 5-year survival rates of up to 60% (20). Local recurrence 
rates can be as high as 54% (21) (22). 
Genomic and molecular markers that can predict disease patterns such as 
lymph node metastasis (23) or survival (24) can prove to be a valuable tool in 
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diagnosing or prognosticating gastric cancer patients. Biomarkers are also useful in 
optimizing the choice of adjuvant therapy (25) (26). 
 
 
Table 2. TNM staging adapted from UICC 6th edition (2002) 
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1.6 Current research directions in gastric cancer 
 
The development of high-throughput technologies such as microarrays has 
ushered in an era of research characterized by the extensive use of statistics and 
bioinformatics. Microarrays can be classified in various ways. Arrays can be 
constructed on glass slides, silicon substrate or even beads. The genetic probes on the 
arrays may be complementary-DNA, oligonucleotides or small PCR fragments. These 
probes are typically deposited on the substrate by spotting with fine-pointed pins, 
inkjets or photolithography. Arrays can be designed for single channel or double-
channel usage depending on the need for absolute quantitation versus relative 
estimation of one sample in comparison to another. Microarrays may be used to detect 
DNA or RNA. Gene expression studies typically employ cDNA arrays while SNP 
(single nucleotide polymorphism) studies usually involve oligo-arrays.  
 
Gastric cancer, like any other malignancy, is characterized by multiple genetic 
and epigenetic alterations. Intense research into the molecular biology of gastric 
cancer over the past 20 years has revealed 3 pathways for gastric carcinogenesis as 
mentioned in section 1.3.2. The 2 classical pathways are shown overleaf. The more 
recently described SPEM pathway has yet to be fully characterized. 
 
By far the most well known is the intestinal pathway and this is to be expected 
since it is the most common form of gastric carcinoma encountered in clinical 
practice. However, the breakthrough discovery of E-cadherin has catapulted the 
diffuse pathway to prominence in recent years. All these pathways are characterized 
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by alterations of the genome in 3 fundamental ways: chromosomal instability, 




Figure 3. Genetic (blue) and epigenetic (green) alterations in gastric carcinogenesis. [Adapted from pg 
70 of reference (27)] 
 
 
 One of the limitations of conventional molecular research is that it fails to 
address non-coding regions of the genome i.e. the gene deserts. Several techniques 
such as comparative genomic hybridization (CGH) have been developed to address 
this shortcoming and our laboratory has had some experience with these. 
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 A previous study in our laboratory using metaphase-spread conventional 
comparative genomic hybridization (CGH) had demonstrated significant copy number 
gains and losses in gastric cancer tissue (24).  
 
 
Figure 4. Chromosomal gains and losses in gastric cancer patients. Gains are shown as green lines and 
losses as red lines. Thick solid lines are highly amplified regions. (24) 
 
1.7 Array CGH 
 
 The chromosomal changes such as gene amplification and deletions can often 
be detected by an increase or decrease in the amount of genomic DNA within the cell. 
This was the basis of a technique first described by Kallioniemi in 1992 which utilized 
competitive simultaneous in situ hybridization of fluorescent-labeled tumor and 
normal DNA in equimolar quantities to a normal human metaphase spread. Regions of 
relative amplification and deletion could then be identified by measuring the color 
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ratio of the two fluorescent dyes (28). This technique is now known as comparative 
genomic hybridization (CGH). 
 
 However, usage of metaphase chromosomes limits the detection of 
abnormalities involving short regions (< 20 Mb) of the genome. Microarray 
technology when applied to CGH, using a spotted array of mapped sequences instead 
of metaphase chromosomes overcomes the limitations of conventional CGH (29). The 
initial attempts were made with cDNA arrays but eventually the use of BAC-arrays 
has come to be recognized as a better way to determine regions of chromosomal gains 
and losses. The resolution of the array would then be a function of the length of the 
spotted sequences and the distance between the sequences on the human genome. 
 
 BAC is an acronym for bacterial artificial chromosome. It was developed in 
1992 as a means of cloning long sequences (>300kb) of the human genome and it 
remains a useful tool for accurately replicating long sequences of human DNA (30). 
A BAC-array is a DNA-microarray that uses BAC clones as the spotted probes instead 
of the usual cDNA or oligonucleotides. 
 
 The advantages of BAC array CGH over conventional metaphase-spread CGH 
include higher resolution (1 Mb vs. 20Mb), simultaneous coverage of the entire 
genome and the requirement of smaller amounts of test DNA (300-500 ng vs. 1 µg) 
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1.8 Objectives of this study 
 
The objective of this study is to utilize BAC array CGH to document the 
genomic aberrations in matched samples of gastric carcinoma, dysplasia, intestinal 
metaplasia and adjacent normal mucosa. The intention is to discover whether or not 
there is a steady progression of genomic copy number changes that parallels the 
transformation of susceptible mucosa into overt carcinoma. This could be the first step 
in an effort to discover possible regions of translocation, duplication or deletion. 
Although outside the scope of this study, the eventual potential discovery of break-
points or duplicated/deleted genes could provide possible diagnostic, therapeutic or 





Materials & Methods 
 
2.1 Obtaining samples 
 
 Records for all patients who had undergone gastrectomy for cancer at the 
Singapore General Hospital for the last 5 years were traced. Their pathology records 
were screened to identify gastrectomy specimens that contained all 4 histological 
types that we required for our study: adjacent normal mucosa, intestinal metaplasia, 
dysplasia and overt carcinoma. 
 A total of 15 suitable gastrectomy specimens were obtained in this manner. 
The original formalin-fixed paraffin-embedded (FFPE) tissue blocks were then traced 
from the archives of the Department of Pathology. Fresh slices from these blocks were 
fixed on slides and read by our collaborating pathologists to confirm that the blocks 
were suitable for our purposes. 
 Two additional sets of blocks containing all 4 tissue types were obtained from 
collaborators in Malaysia. These were processed in the same manner and had 
diagnosis and suitability re-confirmed by our pathologists. 
 We had the following inclusion criteria: 
1.  Only gastric adenocarcinomas were included in this study 
2.  All tissue was to be obtained from formalin-fixed paraffin-embedded blocks 
3.  All 4 histological types had to be present from blocks harvested from the same 
patient at the same operation. “Adjacent normal” specimens are histologically 
normal samples of gastric mucosa taken from the same paraffin block as 
abnormal tissue. “Distant / Far normal” specimens are only taken from blocks 
that are specifically labeled as the proximal or distal resection margins.
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2.2  Core & Slice 
 
 The initial plan was to sample slices from the archived blocks using Laser 
Capture Microdissection (LCM) (31). However, this was not possible for our study as 
there was no expertise available within the Department of Pathology at that time for 
the procedure. 
 In order to overcome this obstacle to the study, we designed another method of 
sampling the blocks. We had available a machine used for constructing tissue 
microarrays. Using this hollow ‘punch’ device usually employed for obtaining cores 
for tissue microarrays, we were able to obtain cores of tissue from the blocks.  
The procedure was as follows: 
1.  Slices taken from each block were read by the pathologist to identify areas for 
core punch biopsy 
2. 1 mm diameter ‘punch cores’ were obtained from the blocks 
3. A 40-micron height section was taken from the mucosal end of the punch core 
4. A standard slice was taken from the top and bottom of this 40-micron height 
section and prepared on a glass slide 
5. The top and bottom slices were read by a pathologist to confirm that only the 
correct tissue type was present. 
 




 In order to verify that the sampling method was accurate for our purposes, 
genomic DNA was extracted from a xenoimplanted tumor established from gastric 
cancer cell line (SNU-5) and tested on CGH and aCGH using recommended 
protocols. The results were compared against the known genomic profile of the 
carcinoma in our records. At a slice thickness of 40 microns, we were able to obtain 
enough DNA of sufficient quality that the aCGH profile of this extracted DNA 
matched the known genomic signature of the SNU-5 cancer. 
 A literature search revealed that a similar form of microdissection had just 
been described by another group (32) (33). The method described by Paris et al. used 
a hollow bore instead of a tissue micro-arrayer punch. We also differed in that we did 
not use the entire core but instead opted to use only a thin section of the core, thereby 
allowing for an additional verification step of the top and bottom slices of this section. 
We believe that the accuracy of our method would be enhanced since the possibility of 
non-target tissue within the 40-micron-height section would be minimized. 
 Since LCM is employed on very thin single slices mounted on glass slides, the 
potential disadvantage of our sampling method compared to LCM would be the 
possibility of harvesting non-target tissue within the 40-micron space. However, given 
the minute amounts of DNA available from a typical LCM specimen, whole genome 
amplification (WGA) is inevitably necessary. WGA would potentially introduce 
Fig 6. Section of the ‘punch core’ 
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artefactual copy number aberrations if the genome is not uniformly amplified. WGA 
methods like multiple displacement amplification (34), degenerate oligonucleotide-
primed PCR (35), ligation-mediated PCR (36) and primer extension preamplification 
(37) are known to introduce copy number bias of dispersed genomic regions (38). The 
advantage of our sampling method is that it allows isolation of sufficient DNA from 
the sample itself, precluding the necessity for an additional WGA step. 
 
2.3 DNA extraction 
 
 We used a commercial kit (PureGene from Gentra Systems Inc) to extract the 
genomic DNA from the formalin-fixed paraffin-embedded tissue (FFPE) sections. The 
protocol is detailed in Appendix 1. Briefly, the process involves de-paraffinization of 
the sample with xylene which is subsequently removed with 100% ethanol.  
A cell lysis solution and proteinase K are then added in the second step which 
typically lasts 3 hours to overnight. This is followed by RNAse A treatment before 
proceeding with protein precipitation.  
Finally the DNA is precipitated with isopropanol and glycogen. The cell lysate 
is centrifuged at 16000 g for 5 minutes and the supernatant drained to obtain a pellet 
of purified DNA which is then hydrated to 20µL of solution.  
The DNA concentration is then quantified with Nanodrop ND-1000 
spectrophotometer (Thermo Fisher Scientific Inc.). The typical yield from a 40-micron 
section was 30-40 ng/µL giving an overall yield of 600-800 ng. The DNA is then 




2.3.1 Reference DNA 
 
 The procedure of CGH necessitates a reference DNA sample for use in the 
competitive hybridization process. For our controls, we elected to use a pooled 
reference DNA comprising equal amounts of DNA harvested from formalin-fixed 
paraffin-embedded (FFPE) splenic tissue from 15 normal human males. 
Fig 7. Flowchart for purification of 
DNA from FFPE tissue. 
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 The reasons for this decision are: 
1. In order to study the adjacent normal tissue profile, we could not use the 
histologically normal adjacent gastric tissue itself as the reference DNA 
sample. 
2. The use of patient blood as a reference DNA posed 2 problems: 
 a. The blood was often not available for most patients in our study 
b. The use of lymphocyte DNA of a much higher quality than the FFPE 
test specimens could introduce biases in the detected copy number 
results. 
3. Since none of the patients had their own matched non-gastric FFPE tissue for 
use as a reference DNA source, the reference DNA was sourced from patients 
not part of the study group. 
4. Pooled genomic DNA from 15 patients was used as a reference to minimize 
the possibility that 1 sample alone may have some idiosyncratic copy number 
aberration itself.  
5. FFPE splenic tissue was used as few stomachs (or indeed any other organ) are 
usually removed in surgery unless there is a gross abnormality. Spleens are the 
exception as traumatic life-threatening splenic rupture is often routinely treated 
with splenectomy. These spleens are normal in size, structure and histology. 
 
The pooled spleen reference DNA was compared to a DNA sample from a 
lymphocyte source which we had previously identified as normal. The resulting array 
image can be seen in section 3.1.2 and the corresponding karyogram in section 3.1.5. 
This was taken as confirmation that our pooled DNA was a valid reference point for 
our study. 
 22 
2.4 Digestion of genomic DNA 
 
 This is the first step in the process of labeling DNA for hybridization (see 
Appendix 2). We used DpnII as the restriction enzyme in this step and the mixture 
was incubated at 37°C for at least 5 hours to allow the reaction to run to completion. 
 
2.5 Purification of DNA 
 
The digested products had to be purified in order to filter out unnecessary 
fragments that could have added to the ‘noise’ in the hybridization images. We used 
another commercial kit for this stage (QIAquick PCR Purification Kit from Qiagen 
Inc.) (see Appendix 2). 
 
2.6 Labeling and hybridization 
 
 We obtained our BAC arrays from the University of California San Francisco 
(UCSF) Comprehensive Cancer Center Microarray Core facility. The specific array 
used was the HumArray 2.0 with an average spacing between clones of 1.4Mb (39). 
This BAC array comprised 2464 BAC clones spotted in triplicate (7392 spots) on a 
coated glass slide. 
The protocol for BAC array hybridization was modified from that used by the 
UCSF core facility (http://cancer.ucsf.edu/array/protocols/index.php). The detailed 
protocol can be found in Appendix 2 and Appendix 3. 
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Briefly, we started with equal amounts (at least 500ng) of test and reference 
genomic DNA. The DNA was first denatured at 99°C with a random primer solution 
(Bioprime DNA labeling system from Invitrogen Inc.).  
The mixture was then cooled on ice before adding Klenow fragment DNA 
polymerase (Bioprime DNA labeling system from Invitrogen Inc.) together with a 
mixture of 0.2 mM unlabeled dATP, dCTP, and dGTP; 0.1 mM unlabeled dTTP. 
Finally, either Cyanine-3-conjugated dUTP (test DNA) or Cyanine-5-conjugated-
dUTP (reference DNA) was added to the mixture. (The cyanine-conjugated-dUTP 
dyes were sourced from Amersham/GE Healthcare). The entire mixture was then 
incubated at 37°C for at least 4 hours. 
We used Microcon YM-30 Centrifugal Filter Units (from Millipore Inc.) to 
remove unincorporated nucleotides from the labeling reaction. At this stage it was 
possible to assess the labeling efficiency by the intensity of the color of the flow-
through. The concentration of the labeled product was then measured with the 
Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific Inc.). 
 As preparation for the hybridization process, we combined equal amounts 
Cy3-dUTP-labeled test DNA and Cy5-dUTP-labeled reference DNA with human Cot-
1 DNA (from Invitrogen Inc.) and precipitated the mixture using 3M pH5.2 sodium 
acetate and ice-cold 100% ethanol. The samples were allowed to fully precipitate for 
60 minutes at -20°C and then centrifuged at 16,100 rpm at 4°C for another 60 minutes 
to produce a violet-colored pellet of labeled genomic DNA. The pellet was then left to 
dissolve in the dark for an hour in a 60µL of a pre-hybridization solution comprising 
10% dextran sulfate, 2× SSC, 50% formamide, 4% SDS, and water. 
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 The labeled gDNA mixture was then denatured at 73°C and then incubated at 
37°C for an hour to allow pre-annealing of the Human Cot-1 DNA to the labeled 
probes. 
The array boundaries on the glass slide are virtually invisible to the naked eye 
and we marked these using a diamond-pen under phase-contrast microscopy. We then 
applied Hybaid EasiSeal 65µL Frames (Cat.No.HBOSSSEZ2E from Fisher Scientific 
Inc.) around each array. The arrays were then placed on a slide warmer at 37°C for 10 
minutes.  
The pre-hybridization solution was again employed, this time as a wetting 
solution on the slide arrays. Once the wetting solution was re-aspirated, the 
hybridization mixture itself was applied to the array. The glass slides were placed in a 
horizontal position arrays facing up in a slide box containing some washing solution 
(50% formamide and 2× SSC at pH7) in the base to maintain humidity. The box was 
sealed with parafilm and placed on a slow rocker at 37°C for 48-68 hours in the dark. 
Post-hybridization, the slides were washed in a solution of 50% formamide 
and 2× SSC at pH7 at a temperature of 50°C for 20 minutes and then in PN buffer 
(0.1M Na2HPO4, 0.1% nonidet P40) at room temperature for 15 min. A final rinse in 
2X SSC solution preceded the serial dehydration with ethanol solutions. The slides 




Fig 8. Diagram summarizing the hybridization process 
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2.7 Imaging and post-processing 
 
We obtained our array images using an Axon GenePix 4000B laser scanner 
(Molecular Devices Inc.). This is a dual-laser scanning system at wavelengths of 532 




The combined color image was then obtained with green signifying a relative 
abundance of test gDNA and red a relative deficiency of test gDNA. Yellow would 
signify relatively equal amounts of both test and reference gDNA (see images in 
section 3.1.2). 
The combined color image was then broken down to its component 
monochrome images at 532 nm and 635 nm (obtained directly from the scanner). The 
monochrome images were then rotated through 90 degrees in preparation for post-
processing beginning with SPOT and SPROC software. 
Fig 9. Genepix laser scanner 
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SPOT is the software developed at UCSF to analyze the array images. SPOT 
functions to provide statistics about each spot on the array (such as log2 ratios of the 
total integrated Cy3 and Cy5 intensities) in addition to performing local background 
correction for each spot (40). SPROC is the companion program to SPOT that maps 
each spot on the array to a specific clone and chromosome position, and averages over 
replicate spots in order to output a final ratio value for each clone on the array (40). 
SPROC contains information on a number of clones which have been found by 
UCSF to be ‘bad’ clones. These are essentially clones that did not transfer adequately 
during the manufacture of the array (i.e. when the array was printed on the glass slide 
at UCSF). Using SPOT and SPROC, a modified SPOT file is first created. This is put 
through a normalization process using the Statistical Microarray Analysis (SMA) 
package in the R environment (www.r-project.org). The normalized log2 
(test/reference) ratios are then used as the new input into the modified SPOT file. This 
new SPOT file is then used to run SPROC again to obtain a final SPOT and SPROC 
output file for further analysis. 
 
2.8 Problems with the hybridization process 
 
2.8.1 Quality of DNA from FFPE tissue 
 
 Numerous reports abound on the difficulty of obtaining good quality DNA 
from formalin-fixed tissue (41) (42). Although formalin is excellent at preserving the 
morphological structure of tissues, it is also a crosslinking agent that induces chemical 
modifications and fragmentation of nucleic acid structures (42). Although the gold 
standard for molecular analyses remains unfixed fresh or snap-frozen tissues these 
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preservation methods cannot be used for our study because they do not provide 
accurate morphological details sufficient to distinguish the histological features of 
metaplastic and dysplastic mucosa within the stomach. 
 In order to gauge the quality of our extracted DNA, we ran several gels to 
determine the degree of fragmentation of the genetic material. From the image in 
Figure 10 below it is clear that the DNA from FFPE tissue comprised smaller 
fragments compared to DNA from a blood lymphocyte sample. This was a clear 
indicator that we could expect poorer results than we had from fresh tumor tissue. 
 
Fig 10. DNA from FFPE tissue comprises significantly smaller fragments. First marker is GeneRuler 
100bp DNA Ladder Plus (Fermentas) and the second is GeneRuler 1kb DNA Ladder (Fermentas). 
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2.8.2 Quality of hybridization results 
 The procedures for hybridization when we began our study in 2004 were 
relatively primitive compared to the alternatives for automated hybridizations today. 
As such there was a steep learning curve in our initial efforts. Our first few attempts at 
hybridization were unsuccessful in large part due to small oversights in the 
complicated hybridization or washing process. Examples include loss of the labeled 
probes at some stage; uneven coverage of the array by the hybridization mixture and 
increased background noise from particulate contamination. 
 Fortunately, these obstacles are largely operator-dependent and once we 
mastered the protocol, there were few further errors. 
 
Fig 11. Examples of poor hybridizations
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2.9 Determination of threshold 
 
 Unlike conventional CGH on metaphase spreads where log2 (test/reference) 
values of more than +0.3 signify amplifications and less than -0.3 signify deletions, 
the determination of significant copy number changes in array CGH is less 
straightforward. Measurement variation varies from hybridization to hybridization and 
hence the threshold of one may differ from another. 
 We adopted the method described by Douglas et al. (43). The first step was to 
establish regions of modal copy number in independent normal versus normal 
hybridizations. We used our pooled spleen reference DNA for this purpose and 
performed 3 sets of hybridizations. Based on the autosomal chromosomes, a threshold 
log2 ratio value of +/- 0.232 representing the 99% confidence interval of normal copy 
number was determined. Thereafter, modal regions in subsequent hybridizations 
involving test versus reference samples were defined by the above threshold, and used 
to calculate the coefficient of variation and 99% confidence intervals. Log2 ratios 
falling above and below these 99% confidence intervals were then deemed as 
amplifications and deletions. 
 In order to further refine our data analysis specific to the identification of 
potential regions of changes, we opted to exclude copy number changes reported by 
only one or two neighboring clones. We thus required changes in at least 3 contiguous 
clones before we considered a region of genomic DNA to be amplified or deleted. 
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2.10 Data analysis and the development of ACAVIS 
 
 We discovered that it was difficult to visualize the overall gross changes 
simply by analyzing the datasets of the 2464 clones in software like Microsoft Excel 
alone. We were therefore obliged to develop our own software for this purpose.  
Array CGH Analysis and Visualization (ACAVIS) is the result of our 
collaboration with faculty members from Nanyang Polytechnic. The program is 
written in Java and primarily functions to provide graphical representation of the 
numerical data from SPOT and SPROC. 
The images generated include genome-wide karyograms as well as 
representations of individual chromosomes. Options exist to view the data as lines or 
as outliers/points only. In addition, the ability to represent up to 20 different samples 
in one image at the same time vastly simplifies the search for obvious regions of 
differences. 
In addition to its graphical functions, ACAVIS integrates several statistical 
functions such as filtering and LOWESS (Locally Weighted Scatter plot Smoothing) 
which allow us to analyze the data from various perspectives. It can also show the 
frequencies of gains or deletions as a sidebar on the chromosome. 
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Fig 12. Screenshot of ACAVIS showing the chromosome 8 profile of an individual sample 
 
 
Fig 13. Screenshot of ACAVIS showing the chromosome 8 profile of 17 samples  
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Chapter 3 
Results & Initial Analysis 
 
3.1 Sample results 
 
3.1.1 Sample acquisition results 
 
A total of 57 specimens were obtained and histologically confirmed by our 
collaborating pathologist. As illustrated in the Table 3, the majority of patients had 
intestinal-type carcinomas with only one having diffuse-type cancer. Unfortunately, 
we were unable to obtain further clinical information on the 2 specimens from 
Malaysia. 
 
Table 3. Details of the 17 patients 
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 Of the 17 patients, we were unable to recover some tissue types from the 
archived FFPE blocks. This was, in almost all cases, due to tissue quality issues which 
were flagged by our pathologist. Table 4 below illustrates the sample types available 





Normal Metaplasia Dysplasia Tumor Total 
1 √ √ √ √ 4 
2 √ √ √ √ 4 
3 √ × √ √ 3 
4 √ √ × √ 3 
5 √ √ √ √ 4 
6 √ √ √ √ 4 
7 √ √ √ √ 4 
8 √ √ √ √ 4 
9 √ √ √ √ 4 
10 √ √ × √ 3 
11 √ √ √ √ 4 
12 √ × √ √ 3 
13 √ × √ √ 3 
14 √ × √ √ 3 
15 √ × √ √ 3 
16 √ × × √ 2 
17 √ × × √ 2 
          57 
Table 4. Specimens by tissue type 
 Given that one patient had diffuse-type carcinoma, 2 had indeterminate 
pathology and 3 had mixed-type pathology by Lauren classification, we were hesitant 
to include them in our analysis since our initial goal was to investigate the genomic 
changes along the Correa pathway of intestinal-type carcinogenesis. 
 However, as will be evident in the later analysis, stratification by Lauren type 




(a) Adjacent normal (top slice of a 40 micron section) 
 
 
(b) Intestinal Metaplasia (bottom slice of a 40 micron section) 




(c) Dysplasia (close up view of a top slice) 
 
 
(d) Carcinoma (close up view) 
Fig 14 (c) & (d) (cont.) Histology from 40 micron sections
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3.1.2 Hybridization images 
 
Figures 15, 16 and 17 are typical hybridization images obtained for different 
tissue types immediately after acquisition with the Axon GenePix scanner: 
 
 
Fig 15. Hybridization image of lymphocyte normal versus pooled spleen reference showing no obvious 






Fog 16. Hybridization image of adjacent histologically normal gastric mucosa of a gastric cancer 






Fig 17. Hybridization image of overt gastric carcinoma versus pooled spleen reference 
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3.1.3 Image processing 
 
The SPOT and SPROC software required the images to be separated into 
individual 532nm and 635 nm intensities before the values could be entered. SPOT 
also read the data from each clone in a horizontal fashion thus necessitating rotation of 


















Fig 20. Image after processing with SPOT 
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3.1.4 Conversion of image data to copy number values expressed as Log2 ratios 
 
We used SPOT and SPROC (from the UCSF Microarray Core website) to 
convert the intensity data from the GenePix scanner to numerical data and Log2 ratios. 
The screenshots in Figures 21 and 22 show the typical output from these programs. 
 
 
Fig 21. Screenshot showing a typical SPOT output in Microsoft Excel format 
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Fig 22. Screenshot showing a typical SPROC output in Microsoft Excel format 
 
As mentioned in section 2.7 earlier ‘bad’ clones were removed at this stage before we 
applied the Statistical Microarray Analysis (SMA) package in the R environment 
before regenerating the final SPOT and SPROC output for further analysis. 
 
 
3.1.5 Conversion of data to graphical representation of Copy Number 
 
 Figures 23-27 illustrate the typical graphical output from ACAVIS in the line 




Fig 23. Genome-wide karyogram of lymphocyte normal versus pooled spleen reference showing 




Fig 24. Genome-wide karyogram of carcinoma vs. pooled spleen reference showing gross abnormalities 







Fig 25. Magnified view of chromosome 8 in a carcinoma vs. pooled spleen reference in line format 
(left) and in outlier format (right) 
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Fig 26. Combined genome-wide karyogram of 4 hybridizations from the same patient. Green represents 




Fig 27. Magnified chromosome 8 (in outlier format) from the preceding karyogram 
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3.2 Combined results for all 17 patients 
 
 57 samples were successfully hybridized versus the pooled spleen reference as 
shown in the Table 5. 
 
Table 5. 57 hybridizations from the 17 patients 
 
3.2.1 Similarity of copy number profiles between the tissue types 
 
The combined results of all 17 patients yielded an interesting pattern. All the 4 
tissue types in each patient tended to appear highly similar in terms of the general 
trend of amplifications and deletions. This result was consistent both in graphical 





Fig 29. Screenshot of Excel spreadsheet showing similar areas of copy number abnormalities in 17 
adjacent normal and 17 cancer samples.
Fig 28. Chromosome 8 profiles of 
adjacent normal (green) and cancer 
(purple) in one patient showing a similar 
pattern of copy number abnormalities 
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3.3 Analysis of the combined results for 17 patients 
 
3.3.1 Combined karyogram of all 17 patients 
 
Fig 30. Genome-wide karyograms of adjacent normal (above) and carcinoma (below) for all 17 patients 
shows similarities although the sheer amount of overlapping data precludes close comparison on this 
view. 
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 In order to better examine this finding of widespread similarity, we decided to 
focus on 2 tissue types instead of 4. Our reasons were: 
1. All 17 patients had adjacent normal and tumor tissues allowing a greater 
sample size as a basis for comparison 
2. The theoretical difference between tissue types should be greatest between 




Fig 31. Magnified view of chromosome 8 for all 17 patients shows similar copy number changes 
between adjacent normals and carcinoma. The green and red bars represent the frequency of the copy 
number abnormality occurring with values ranging from 0 to 17 patients. There are 17 colors of dots 
representing the 17 patients. 
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3.3.2 Additional Tables & Graphs for all 17 patients  
 
 The bar charts in Figure 32 demonstrate that the similarity of adjacent normal 
and tumor tissue types occurs across the entire genome in our group of 17 patients. 
 
Fig 32. Bar charts of clone position on the x-axis versus % frequency (out of 17) on the y-axis 
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Fig 33. Bar chart summarizing the copy number changes present in ≥ 50% of 17 patients. Changes in 
adjacent normal mucosa appear as short orange bars and in tumor mucosa as long green bars. (Bar 
lengths do not denote frequency of occurrence.) The changes are ordered according to clone order from 
chromosome 1 to Y. Grey vertical lines demarcate chromosomes 
 
 
 The chart in Figure 33 illustrates that with few exceptions (e.g. position 211) 
the changes that occur in a majority of the 17 adjacent normals tend to be mirrored in 
the corresponding 17 cancers as well and vice versa.  
Table 6 on the next page summarizes the regions of similar copy number 
changes in both tumors and adjacent normal gastric mucosa. Examination of 
chromosome 8q, which we know to be highly amplified in gastric cancer, reveals that 









































 The next attempt at classifying the data was involved determining if the 
genomic profiles of the samples clustered according to any particular pattern. We used 
Cluster 3.0 and TreeView, both written by Michael Eisen from the Howard Hughes 
Medical Institute at the University of California at Berkeley 
(http://rana.lbl.gov/EisenSoftware.htm).  
 Using average linkage unsupervised hierarchical clustering and TreeView, we 
generated the cluster diagram seen in Figure 34. The long image on the left is the 
entire group of clones going down vertically with the 37 samples going across 
horizontally. The image on the right is a magnified section taken from the main image 
with the tree at the top also magnified. 
 On the horizontal axis, C represents spleen versus spleen controls. T represents 
carcinoma and N represents adjacent histologically normal mucosa. I, D and M 
represent the Lauren classifications of intestinal, diffuse and mixed pathologies. For 
example, TI represents an intestinal-type tumor. 
 The dendrogram (at the top of Figure 34) and the order of the columns after 
unsupervised hierarchical clustering demonstrate that the controls are fundamentally 
different from all the other samples. The second conclusion that can be gleaned from 
the cluster diagram is that there is no evidence of any segregation between cancers and 
adjacent normals regardless of Lauren type. Neither is there any evidence of grouping 
according to Lauren type although it should be recognized that the small numbers of 




Fig 34. Cluster and tree view of 17 tumors, 17 adjacent normals and 3 controls. C 
represents spleen versus spleen controls. T represents carcinoma and N represents 
adjacent histologically normal mucosa. I, D and M represent the Lauren 
classifications of intestinal, diffuse and mixed pathologies. X is undifferentiated. For 
example, TI represents an intestinal-type tumor (see text) 
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3.3.4 Regions of interest different between normal and tumors 
 
 Despite the fact that the bar charts and the cluster diagram so eloquently 
illustrate the genomic similarity of tumor and adjacent normal tissues, it is 
nevertheless tempting to probe into possible differences between these two tissue 
types in an effort to discover possible regions of interest which may contain sequences 
that propel genetically altered adjacent mucosa down the road to overt carcinoma. 
 Using the data used to construct the bar charts in section 3.3.2, we searched for 
BAC clones for which the difference in the frequency of a copy number aberration 
was greater than 5%. The cytoband was then matched against the UCSC (University 
of California at Santa Cruz) Genome database to identify the RefSeq genes present in 
these regions.  
 




Genes Normal Tumor 
1 RP11-138K16 1p21.2 99419-99595 41 53 Del PALMD 
2 RP11-94D19 3p14.2 60739-60909 47 53 Del FHIT 
3 RP11-19I19 5q11.2q12.1 58769-58928 41 59 Del PDE4D 
4 RP11-47N20 5q14.1q14.2 81388-81542 47 59 Del 
APG10L, 
ATG10 
RP11-207B2 5q14.2 81757-81757 41 53 Del  
5 RP11-66E14 6p24.3 8799-8799 47 65 Del  
6 RP11-193J17 7q11.22 71146-71146 47 53 Amp CALN1 
7 
RP11-9C22 7q32.1 127170-127170 47 65 Amp SND1 
CTB-162H9 7q32.1 127287-127287 41 65 Amp SND1 
8 RP11-182C2 10q25.1 111415-111495 47 53 Del ADD3 
RP11-182P7 10q25.2 111544-111544 47 53 Del ADD3 
9 RP11-265I6 18q12.3 35981-36148 47 53 Del  
Table 7. Frequency table of cytobands and genes in corresponding regions 
 
 From Table 7, it can be seen that the regions with the greatest differences in 
copy number frequencies between tumor and adjacent normal involve amplification of 
7q32.1 and deletion of 5q11.2q12.1.  The respective genes in those regions are SND1 
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and PDE4D. Little is known about SND1. PDE4D is known to encode functional 
proteins that degrade the cAMP, which itself is a key signal transduction molecule. 
Up-regulation of PDE4D may play an important role in epithelial-mesenchymal 
transition (44). 
 
3.4 Initial conclusions 
 
 The obvious conclusion was that tumor and adjacent normal gastric mucosa 
were genomically alike. Given that the morphological and histological appearances of 
these two tissue types are vastly different from tumor, this was a difficult conclusion 
to accept initially. 
 
 The consideration of other possibilities to account for the experimental 
findings included possible tissue contamination, whether at the initial sampling stage 
or further down the line at the primer stage, or even at the hybridization stage if any 
reagents had been compromised. We repeated several hybridizations on samples with 
excess DNA using fresh reagents and clean equipment and our findings were similar. 
 
 Another potential source of bias was the FFPE tissue. Given the notorious 
cross-linking of DNA known to occur in this circumstance, we could not quantify the 




 The unexpected experimental findings prompted the decision to embark on a 
series of further experiments to either confirm or refute our findings. To that end the 
next set of experiments were designed to contemplate the following questions: 
1. Are there significant copy number changes in the margin blocks of the 17 
patients? 
2. Would freshly harvested gastric tissue with minimal formalin fixation 
processing produce similar results? 
3. Are there significant copy number changes in DNA from the FFPE gastric 





In order to determine if our results were indeed true or perhaps due to 
experimental error, we proceeded to perform 3 further sets of experiments: (a) array 
CGH on the stomach tissue of non-cancer patients; (b) array CGH profile of the 
margin blocks from the initial set of patients; and, (c) array CGH on freshly harvested 
gastric cancer specimens. ‘Margin blocks’ contain paraffin-embedded formalin fixed 
tissue taken from the proximal and distal resection margins of gastrectomy specimens. 
 
4.1 Stomach tissue from non-cancer patients 
 
This experiment was designed to demonstrate or exclude the possibility that 
there was tissue contamination at some point along our sampling or hybridization 
procedures. Samples were obtained from gastrectomies for perforated or bleeding 
benign peptic ulcers 
 
4.1.1  Methodology 
Samples were obtained from patients who had undergone gastrectomy for non-
cancer diagnoses. We were only able to obtain specimens from 2 patients who had 
undergone gastrectomy for large perforated ulcers. The relative scarcity of such 
gastrectomies today is testimony to the efficacy of proton-pump inhibitors and the sea-
change in management of peptic ulcer disease. 
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Specimens from both patients were processed in a similar fashion, undergoing 
formalin-fixation and paraffin-embedding. The coring process and the verification of 
the 40 micron sections were also performed as previously described. 
 
Subsequent DNA extraction, random primer labeling and hybridization were 
conducted in identical fashion as for the 57 previous specimens. The arrays were 




Patient Age Sex Race Surgery 
Non-cancer patients 
1 76 F Chinese 2005 
2 49 M Chinese 2005 
Cancer patients 
1 80 M Chinese 2004 
2 78 F Chinese 2004 
3 - - - 2004 
4 50 M Chinese 2000 
5 81 F Chinese 2004 
6 81 M Chinese 2002 
7 66 M Chinese 2001 
8 65 M Chinese 2002 
9 83 M Chinese 2004 
10 65 M Chinese 2002 
11 80 M Chinese 2003 
12 69 M Chinese 1999 
13 85 M Chinese 2000 
14 63 M Chinese 2002 
15 76 M Chinese 1999 
16 75 F Chinese 2004 
17 - - - 2004 
 
Table 8. Comparison of 
non-cancer (benign ulcer) 
patients with cancer 
patients 
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The epidemiological data of the non-cancer patients with benign ulcers who 
underwent gastrectomy is summarized in Table 8. No data is available on the NSAID 
usage and Helicobacter pylori status of the cancer patients. Surgery denotes the date 
the paraffin block was created. 
 
 The hybridization image in Figure 35 shows a relatively uniform yellow color 
across most of the BAC clones suggesting that there are few deletions or 
amplifications. 
 
Fig 35. Hybridization image of gastric mucosa from non-cancer patient vs. pooled spleen reference 
 
The genome-wide karyograms for both non-cancer patients in Figure 36 show 
that despite the yellow appearance of the hybridization image, there are a number of 
copy number changes present. 
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Fig 36. Genome-wide karyograms of both non-cancer patients 
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However, on closer inspection and comparison with the karyograms seen in 
Chapter 3, it is fairly evident that both the number and magnitude of the copy number 
aberrations are greatly reduced in the non-cancer patients. This is perhaps most 
obvious in magnified views of single chromosomes seen in Figure 37 below. 
 
Fig 37. Chromosome 8 profile of both non-cancer patients compared to a tumor specimen 
 
 There is also a notable reduction in copy number aberrations in these non-
cancer specimens in comparison to the adjacent normal specimens from both the 
archived tissues as well as from 3 newly-processed prospective samples as seen in 
Figure 42 (in Section 4.3.2) 
The data from these 2 non-cancer patients was then added to the cluster 
analysis described in section 3.3.3. The resultant cluster and tree diagram is shown in 
Figure 38. The same abbreviations apply as in section 3.3.3 with the addition of U to 
represent the 2 non-cancer Ulcer patients. 
It is immediately obvious that the 2 non-cancer patients cluster together with 






Fig 38. Cluster and tree view of 17 tumors , 17 adjacent normals, 2 non-cancer ulcers and 3 controls. C represents 
spleen versus spleen controls. U represents the ulcers. T represents carcinoma and N represents adjacent 
histologically normal mucosa. I, D and M represent the Lauren classifications of intestinal, diffuse and mixed 




The obvious difference in the genomic signature of histologically normal 
gastric mucosa from cancer versus non-cancer patients is interesting. This difference 
could perhaps be attributed to one of two possibilities: 
 
1. Histologically normal adjacent mucosa in gastric cancer is genomically 
abnormal with gross copy number aberrations. 
2. The age of the archived tissue versus the recently processed (albeit FFPE) non-
cancer tissue might be a deciding factor in the quality of the DNA, leading to 
differences in the genomic signature. 
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4.2 Distant resection margins of the original group of 17 patients 
 
As mentioned earlier, thus far all the ‘normal’ specimens in the initial 57 
samples in section 3 can be defined as ‘adjacent normals’. This is because they were 
all harvested from the same block as the tumor specimens. 
 
The purpose of this experiment is to determine if the distant resection margins 




In order to perform this additional experiment, we attempted to trace the 
margin blocks of the gastrectomy specimens of our original 17 patients. However, we 
were only able to obtain proximal (gastric) and distal (duodenal) margin blocks for 8 
of the 17 patients. Of the remaining 9 patients, several had no margin blocks available 
and a few had only proximal oesophageal margins after a total gastrectomy. 
 
Table 9 summarizes the characteristics of the margin blocks we were able to 
obtain. Distances of the histologically uninvolved surgical margin to the histologically 
involved edge of the primary tumor are also listed to provide an idea of the magnitude 
in differences of location of these margin specimens from adjacent normal samples. 
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Table 9. Margin blocks of 8 patients 
 
 All the margin blocks were processed as described in Chapter 2. DNA 
extraction, random primer labeling and hybridization were also performed in an 
identical manner. Proximal gastric margins were considered ‘Far Normals’. Distal 
duodenal margins do not comprise gastric tissue and are not considered gastric 




Since the primary aim of this experiment is to determine whether or not the 
margins (Far Normals) have a similar genomic profile as the adjacent normals and the 
tumors, another cluster diagram was constructed. In Figure 39, T signifies tumor, N 
signifies adjacent normal and F signifies far normal. The numerals after each alphabet 
denote the patient number. 
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The appearance of the dendrogram at the top would give the impression that 
unlike the non-cancer patients, these margins do not segregate on a first-order branch. 
However, closer inspection will reveal that despite this, there is a real clustering of the 
Far Normals (proximal margin samples) away from the tumors and the adjacent 
normals. All the margin samples are on the far right of the cluster diagram indicating 
that it highly probable that the margins are at some level fundamentally different from 
the tumor and adjacent normals. 
 
Fig 39. Cluster diagram of 8 tumors (T), 8 adjacent normals (N) and 8 far normals (F) 
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 Taking the comparison one step further, we used the distal duodenal margins 
to subtract away the ‘noise’ in our array CGH signatures. This was done by excluding 
any genomic abnormalities that appeared in the uninvolved duodenal samples as well 
since the duodenal samples do not constitute gastric tissue  
 The cluster diagram was then reconstructed using this dataset (Figure 40) and 
the difference between the far normals and the adjacent normals became more 
pronounced with first order differences emerging in the dendrogram. The far normals 
again cluster tightly on the far right. 
 






















































The DNA from the margin blocks have a distinctly different genomic profile 
compared to the adjacent normals and the tumors. This result establishes several 
points: 
1. The age of the archived tissue is unlikely to be a major factor in determining 
the outcome of our initial experiments. This is clearly shown by the fact that 
different genomic signatures can be obtained from blocks of an identical age, 
with distance from tumor being the only differentiating factor. 
2. Distance from the primary tumor is a significant determinant of genomic 
 instability in histologically normal gastric mucosa in cancer patients 
3. The concept of a zone of ‘cancerization’ surrounding the primary tumor should 
be considered. 
 
 The detailed analysis of cytobands showing copy number aberrations present 
in both adjacent normals and tumors but absent in proximal margin tissues are 
summarized in the Table 10 on the preceding page. Several of the genes have been 
highlighted. 
BRCA2 is a DNA repair gene that is most famously associated with breast 
cancer. There have been a number of reports that have found an association with 
gastric cancer as well (45) (46) (47) (48) and the risk of developing gastric cancer for 
carriers of BRCA2 mutations may be as high as 20 -60% (46). 
MDS1 and EVI1-like gene were recently found to be aberrantly expressed in 
gastric cancer cells (49). It is believed that their action as one of the co-repressors of 
the TGF-β signaling pathway may be involved in gastric carcinogenesis. 
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4.3 Prospective gastric cancers formalin-fixed and paraffin-embedded (FFPE) 
 
 The initial 57 specimens from 17 patients were all acquired from pathology 
archives dating back up to 5 years. The aim of this experiment was to determine two 
things: 
1. Is there a progression of changes from distant normal gastric tissue to adjacent 
normal gastric tissue in cancer patients? 
2. Are there differences between archival FFPE tissue and freshly prepared FFPE 
 issue?  
 
4.3.1 Methodology  
 
 Three patients were identified prior to gastrectomy for cancer as being suitable 
candidates for tissue harvest. Their consent for tissue donation was obtained in the 
usual manner using our institution-standard procedure. 
 Once the stomach was resected, it was examined by a pathologist in the 
operating theatre complex. The pathologist then provided us with samples of the 
tumor itself, adjacent normal mucosa and distant proximal gastric margins. 
 The 3 tissue specimens from each patient were then processed with formalin-
fixation overnight followed by paraffin-embedding the next day by our own 
laboratory staff. 
 Punch core biopsy, sectioning in to 40 micron wedges and verification of the 
top and bottom slices was performed as described earlier. DNA was then extracted 
and hybridized to our BAC arrays with the pooled spleen DNA as reference. 
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4.3.2 Results  
 
Patient Age Sex Race Surgery 
Prospetive patients 
1 69 M Chinese 2005 
2 67 M Chinese 2005 
3 76 M Chinese 2005 
Non-cancer patients 
1 76 F Chinese 2005 
2 49 M Chinese 2005 
Cancer patients 
1 80 M Chinese 2004 
2 78 F Chinese 2004 
3 - - - 2004 
4 50 M Chinese 2000 
5 81 F Chinese 2004 
6 81 M Chinese 2002 
7 66 M Chinese 2001 
8 65 M Chinese 2002 
9 83 M Chinese 2004 
10 65 M Chinese 2002 
11 80 M Chinese 2003 
12 69 M Chinese 1999 
13 85 M Chinese 2000 
14 63 M Chinese 2002 
15 76 M Chinese 1999 
16 75 F Chinese 2004 
17 - - - 2004 




 The epidemiological characteristics of the 3 prospective cancer patients in 
comparison to the other patients is summarized in Table 11 above. Surgery denotes 
the date the paraffin block was created. 
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 The 3 patients were labeled A, B and C respectively. BAC array CGH results 
from this small group of patients were significantly cleaner than for our initial 17 
patients. As an example, the karyogram in Table 41 represents the genomic profile of 
the proximal gastric margin from one of the patients. It is reasonably similar to the 
signature from non-cancer patients in section 4.1.2 and distinctly different from the 
genomic profiles of our initial 17 patients seen in chapter 3. 
 
Figure 41. Genome-wide karyogram for the distant normal specimen of Patient A 
 
 The comparison is more obvious when we place the magnified single 
chromosome view of the 3 patients alongside the results from chapter 3. This is 
demonstrated in Figure 42. 
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Figure 42. Chromosome 8 
profile of different sample 
types from the 3 prospective 
patients (A, B, C) compared 
to similar tissue types of a 
patient from the initial set of 
archived specimens. Tumour 
and adjacent normal samples 
from Patient A were of 
insufficient quantity to 
perform aCGH. A non-cancer 
(benign ulcer) profile is at the 




Figure 43 presents in magnified view the progression of changes in the 3 specimen 
types obtained from this experiment. 
 
 
Fig 43. Chromosome 8 comparison across tissue types from Patients B & C  
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 There is a visible progression of genomic abnormality in the 3 specimens 
obtained from each patient. The tumor specimens show the expected amplifications in 
chromosome 8 characteristic of most gastric cancer samples. The margin samples are 
relatively clean with only a few outliers, similar to the profile from non-cancer 
patients. The adjacent normal tissue is perhaps somewhere in between with a greater 
number of genomic changes than the margin samples. The adjacent samples are also 
characterized by greater amplitudes in the copy number changes. 
 Comparison of the tumor profiles of the 2 patients above with the tumor 
profiles of chromosome 8 in our earlier 17 patients also demonstrates a ‘cleaner’ 
signature despite the characteristic amplifications seen. This reduction in ‘noise’ 
would be helpful when trying to determine area of real genomic aberration as opposed 
to outliers caused by poor preservation or cross-linking of DNA. 
 
4.3.3 Discussion  
 
 The results of this experiment demonstrating the genomic profile in freshly 
harvested FFPE tissue compared to our initial archived FFPE tissue allows us to 
conclude that: 
1. There is a gradual progression of accumulated genomic changes from 
histologically normal margin specimens to histologically normal adjacent gastric 
mucosa to overt carcinoma. 
2. There is a distinct improvement in ‘noise’ reduction when comparing the 
newly processed specimens compared to the archival tissues. This may be related to 
the time from harvesting to fixation, the duration of formalin fixation or perhaps even 
the age of the block itself. 
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Chapter 5 
Final Analysis and Discussion 
 
5.1  Summary of initial results 
 
 The results of the first 57 archived formalin-fixed paraffin-embedded (FFPE) 
specimens from 17 patients were characterized by a relatively ‘noisy’ genomic 
signature despite the use of smoothing algorithms such as the LOWESS technique.  
 Nevertheless, once the thresholds for each specimen were defined using the 
Douglas et al. method (43), a pattern was discernible. The expected genomic 
amplifications and deletions in tumor tissue were seen. There were also a satisfyingly 
large number of changes in dysplastic and metaplastic tissue that mirrored the 
aberrations in tumor tissue. What was unexpected however was the quantity and 
magnitude of changes in adjacent histologically normal gastric mucosa from these 
cancer patients. 
 These aberrations in the adjacent normal mucosa were further analyzed by 
comparing them with the tumor specimens in all 17 patients. There was a marked 
similarity in the genomic signature of adjacent normal tissue with tumor tissue on 
visual inspection of the data using our new ACAVIS software. This was further 
confirmed when the data was represented on bar charts. An unsupervised clustering of 
the tumor and adjacent normal samples failed to detect any pattern of segregation 
between the 34 samples (17 tumors and 17 adjacent normals) with the only conclusion 
being that all 34 were abnormal compared to our control hybridizations. 
 Looking more closely at the regions of similarity, it was discovered that 92 
cytobands which were amplified or deleted in at least 50% of both adjacent normal 
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and tumor specimens. These were too many to characterize as there was no practical 
method available to determine which were more significant than others. 
 The surprising results also raised disturbing questions as to the possibility of 
cross contamination or bias arising from experimental error. This was despite a fairly 
rigorous process during which we had established controls for the reference DNA and 
minimum DNA quantities before hybridization. The controls had been procured from 
similar FFPE sources and self versus self hybridization of these controls had revealed 
no discernible error within the hybridization process. 
 Additional experiments were designed to confirm or refute our initial findings. 
A decision was also made to focus on adjacent mucosa and tumors rather than 
intestinal metaplasia or dysplasia since it was assumed that this would serve to 
accentuate the significance of any findings if the histological types were far removed 
from each other along the pathway of the Correa hypothesis. 
 
 
5.2 Summary of results from further experiments 
 
 The first additional experiment that was performed was on FFPE gastric 
mucosa from non-cancer patients. As expected, the non-cancer genomic signature was 
similar to that of our spleen versus spleen reference control, and completely different 
from the tumors or adjacent normals. This experiment served to confirm that our 
bench work processes were not the source of the unexpected initial results. 
 The second additional experiment examined the margin blocks from the first 
17 patients. As only 8 such blocks were available from the pathology archives, our 
analysis was confined to these alone. Nevertheless, the results were highly significant 
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showing that the margins do not share many of the genomic abnormalities of the 
adjacent normals. Although the genomic signature of the margins themselves were 
relatively ‘noisy’ much like the other 57 original samples, they were clearly less 
aberrant in terms of significant copy number changes and as such all 8 samples 
clustered away from their corresponding tumors and adjacent normals (see section 
4.2.2). The conclusion served to confirm the suspicion that the adjacent normals 
themselves, while histologically normal, harbored extensive genomic aberrations. 
 The final additional experiment involved the collection of fresh cancer 
specimens which were then processed with formalin in our own laboratory. The 
results confirmed the expected progression of changes from distant normal mucosa to 
adjacent normal mucosa to tumor, which was the logical conclusion of the earlier 
experiments. 
 The results from the 3 experiments also demonstrated that the ‘noise’ from the 
older archived pathology blocks was significantly greater than the ‘noise’ seen in the 
specimens processed in our laboratory. This was manifested by a more widely spread 




5.3 Field Cancerization 
 
It is universally recognized that histopathology is the ‘gold standard’ for 
diagnosis of cancer. Therefore it was unexpected that so many significant changes 
were found in non-cancer mucosa in our study. These histologically normal adjacent 
regions harbored many of the same changes that were also found in their 
corresponding tumors. 
The most likely explanation for our findings is the concept of a field change in 
the gastric mucosa. This concept was first proposed in 1953 (50) and it explains why 
the changes are less pronounced or even absent at the distant margins of the 
gastrectomy specimens. The general pathogenesis of a field defect can be seen in the 
diagram on the next page. The theory is that chronic exposure to a DNA-damaging 
agent leads to the clonal expansion of inappropriate cell types that exhibit genetic 
instability. This premalignant state would eventually lead to transformation into overt 
carcinoma. When compared to the Correa hypothesis, it is clear that gastric carcinoma 
falls neatly into this process. The initiator for the field defect would be some sort of 
injury such as chronic gastritis secondary to Helicobacter pylori infection triggering 
the progressive sequence of gastric atrophy, intestinal metaplasia, dysplasia and 
finally carcinoma. 
Another potential trigger for field cancerization in the stomach may be injury 
to the stomach mucosa by bile acids and this is the theory that has been advanced to 
explain the known phenomenon of higher rates of gastric cancer in patients with 
previous partial gastrectomies for peptic ulcer disease. The recent dramatic rise in 
proximal gastric or cardio-oesophageal carcinomas is also supported by this theory of 
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cancerization in which the presence of Barrett’s esophagus serves as an intermediate 
entity in carcinogenesis. 
 
 
Fig 44. General pathway for the development of a field defect (adapted from Bernstein) (51) on the left 
and the Correa hypothesis on the right. 
 
The concept of field cancerization and our discovery that histologically normal 
gastric mucosa harbors many similar changes to carcinoma lends credence to the old 
surgical maxim that the resection margin should be at least 5 cm away from the tumor. 
While it was previously believed that this was to allow for the possibility of 
submucosal microscopic spread of tumor cells, it can now be attributed to the 
propensity of adjacent mucosa to develop cancer.  
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The ability to detect these genomic changes may potentially allow a more 
sensitive method for intraoperative decision-making on the extent of resection. This 
role is currently occupied by frozen section histopathology. Given the superior 
sensitivity of genomic analysis, should a rapid test be available one day, it would 
undoubtedly supplant frozen section not only in gastric cancer but for any malignancy 
that has an element of field cancerization (e.g. head and neck squamous cell 
carcinomas). 
Other cancers that have had reported genetic or structural changes in the 
absence of histopathological evidence of malignancy include colon (52) (53), prostate, 
breast,  esophagus (54) and the upper aerodigestive tract (55) (56).  
The evidence for colon cancer was first reported in 2004 when it was found 
that histologically normal adjacent mucosa had altered gene expression in mice and in 
human cancer patients.  
Proteomic analysis of morphologically normal mucosa in patients with 
colorectal malignancies further confirmed that there were field-wide changes in 
protein expression (57). 
 Further evidence for field cancerization is provided by the recent finding that 
there are nanoscale cellular changes in histologically normal mucosa in colon cancer, 
pancreatic cancer and lung cancer (58) (59). It was found that partial wave 
spectroscopy could quantify statistical properties of nanoscale cell structures (59). The 
disorder strength of the nanoscale architecture was reduced in both tumor cells as well 
as microscopically normal cells adjacent to the tumor. 
 A study of gene expression in prostate cancer and normal-appearing adjacent 
tissue found that both were fundamentally different from prostatic tissue in cancer-
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free organ donors (60). Studies in the breast have also reported genomic instability in 
histologically normal tissues (61) (62). 
Although no reports have yet emerged on genome-wide copy number 
aberrations in histologically normal stomach mucosa, there have been some reports of 
genetic changes in adjacent normal gastric epithelium involving the hMSH2 gene (63) 
and the RUNX3 gene (64).  
 
5.4 Regions of interest 
 
 A systematic review of the genomic alterations in gastrointestinal cancers 
published last year (65) noted that in 45 published reports of CGH, the most frequent 
alterations found in gastric cancer were +20q13 (38.9%), +8q23 (31.7%), -19p13 
(20.9%) and +17q21 (20.5%). All 4 of these aberrations were found in our study 
population (see section 3.3.2) in both tumor and adjacent normal samples. In the 
further subset analysis of 8 sets of samples in section 4.2.2, it was noted that +20q13 
and +17q21 were present in both adjacent normals and tumors but not in proximal 
margin samples.  
 20q13 contains a region encoding for the PTP-RT gene (Protein tyrosine 
phosphatase, receptor type, T). PTP’s are known to be signaling molecules that 
regulate cellular processes such as cell growth, cell differentiation, mitosis, and 
oncogenic transformation. PTP expression has previously been correlated to gastric 
cancer progression (66). 17q21.33 contains genes such as NGFR, NXPH3, SPOP, 
SLC35B1 and FAM117A. Unlike PTPRT, there are as yet no reports linking the gene 
products to gastric cancer. 
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 Examples of other cytobands that have been reported to be involved in gastric 
carcinogenesis include 7p12, 8q22 and 15q22-q25 (67). These were also found in our 
cohort of patients as can be seen in the tables in chapters 3 and 4. 
 Although the gene pathways correlating these regions of genomic abnormality 
may not be well understood yet, the discovery of these regions can have an immediate 
impact on the way we manage gastric cancer. For example, aberrations on 
chromosome 8 have been suggested as a diagnostic marker while chromosome 19 
abnormalities have been associated with younger patients and gains in chromosome 
17 have been linked to rapid tumor progression and poor prognosis (68). 
 
5.5 Issues with FFPE tissue 
 
A recent report suggested that FFPE tissues display abnormally large numbers 
of spurious copy number changes when used for the purpose of array CGH as 
compared to fresh tissue (69). This is certainly consistent with our experience. It has 
been suggested that the presence of necrosis in a tissue specimen has an adverse effect 
on the quality of array CGH as well (70). 
It was unfortunate that the quality of the genomic DNA in the formalin-fixed 
paraffin-embedded tissue in our hospital archives was suboptimal. The results from 
the few prospective specimens processed in our laboratory were significantly cleaner. 
This may have been because of the shorter fixation times since it has been reported 
that fixation times of less than 20 hours do not impact on array CGH results (71). In 
retrospect, in addition to looking at the size of the DNA fragments within our initial 
sample set, it might have been possible to evaluate the DNA quality using more 
recently described methods such as those techniques involving PCR (72) or isothermal 
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whole genome amplification (73) prior to performing array CGH. However, if the 
samples had not passed these qualifying tests, we may have had to use them anyway 
as there was a paucity of specimens available that satisfied our primary inclusion 
criteria. 
 The root of the problem however, appears to lie with the cross-linking action 
of formalin on nucleic acids (42). Some alternative methods of fixation involving new 
fixatives such as methacarn, RCL2 (42), HOPE (74) and FineFix (75) have been 
suggested. However the problem remains that while they may be ideal for a research 
laboratory setting, most hospital pathology departments continue to use formalin 
because it is more economical yet maintains consistency with world-wide standards 
for histopathological diagnosis. The potential requirement for molecular or genomic 
analysis is unfortunately not part of the cost structure of most clinical institutions. 
 
5.6 Further studies 
 
 With the experience from this study, it would be a natural extension to 
consider a more detailed study of freshly harvested tissue processed in our own 
laboratory with one of the new fixatives. Laser Capture Microdissection (LCM) if 
available would be ideal as the sampling method. Using an accurate method of 
isothermal whole genome amplification described one of our laboratory colleagues 
(38), we could then proceed to look at the genomic signatures using a newer array 
such as the 32,000-BAC array, the 500,000-SNP Affymetrix platform or Molecular 
Inversion Probe (MIP) microarrays. 
 Despite our stated aim to study intestinal pathway of carcinogenesis, we were 
only able to acquire 6 complete sets comprising 4 tissue types each. We were also 
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hindered by the similarities and the ‘noise’ inherent in our archival specimens. Should 
a set of freshly harvested tissues be available, this would be ideal to pursue our 
original intention. 
 One other group of patients that would be interesting to study would be non-
cancer patients. If we could acquire a library of non-cancer gastric tissues, it would be 
possible to study their genomic profile in comparison with the margins of gastrectomy 




The study of the human genome is an exploding field exemplified by the surge 
in research effort and publications in recent years. Gastric carcinoma is one of the 
major killers in our society and this study confirms that field cancerization is an 
important concept for this malignancy.  
In addition to explaining recurrences and the etiology of gastric cancer, the 
concept of field cancerization holds the potential for accurate and sensitive genomic 
diagnosis of ‘premalignant’ gastric mucosa that may appear histologically normal. It is 
also likely to be a key area of research in the future as initiators for carcinogenesis are 





1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods 
Mol. Biol. 2009;472:467-477.  
 
2. Griffin MS, Raimes S. Oesophagogastric Surgery: A Companion to Specialist 
Surgical Practice.  3rd ed.  Saunders Ltd.; 2006.  
 
3. Roder DM. The epidemiology of gastric cancer. Gastric Cancer. 2002;5 Suppl 
1:5-11.  
 
4. Lee HP. Singapore Cancer Registry Interim Report: Trends in Cancer Incidence in 
Singapore 2002-2006.  National Registry of Diseases Office, Singapore; 2008.  
 
5. Yeoh K. How do we improve outcomes for gastric cancer? J Gastroenterol 
Hepatol. 2007 7;22(7):970-972.  
 
6. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-
called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta 
Pathol Microbiol Scand. 1965;64:31-49.  
 
7. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988 Jul 
1;48(13):3554-3560.  
 
8. Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K, et al. Gastric 
dysplasia: the Padova international classification. Am. J. Surg. Pathol. 2000 
Feb;24(2):167-176.  
 
9. Schlemper R, Riddell R, Kato Y, Borchard F, Cooper H, Dawsey S, et al. The 
Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000 
Aug;47(2):251–255.  
 
10. Lee HS, Chang MS, Yang H, Lee BL, Kim WH. Epstein-barr virus-positive 
gastric carcinoma has a distinct protein expression profile in comparison with 
epstein-barr virus-negative carcinoma. Clin. Cancer Res. 2004 Mar 1;10(5):1698-
1705.  
 
11. Gutiérrez-González L, Wright NA. Biology of intestinal metaplasia in 2008: more 
than a simple phenotypic alteration. Dig Liver Dis. 2008 Jul;40(7):510-522.  
 
12. Hamilton JP, Meltzer SJ. A review of the genomics of gastric cancer. Clin. 
Gastroenterol. Hepatol. 2006 Apr;4(4):416-425.  
 
13. Gumucio DL, Fagoonee S, Qiao XT, Liebert M, Merchant JL, Altruda F, et al. 
Tissue stem cells and cancer stem cells: potential implications for gastric cancer. 
Panminerva Med. 2008 Mar;50(1):65-71.  
 
14. Takaishi S, Okumura T, Wang TC. Gastric cancer stem cells. J. Clin. Oncol. 2008 
Jun 10;26(17):2876-2882.  
 
 90 
15. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. E-
cadherin germline mutations in familial gastric cancer. Nature. 1998 Mar 
26;392(6674):402-405.  
 
16. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, et al. E-Cadherin 
gene promoter hypermethylation in primary human gastric carcinomas. J. Natl. 
Cancer Inst. 2000 Apr 5;92(7):569-573.  
 
17. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric 
cancer epidemiology. The Lancet. 1975 Jul 12;306(7924):58-60.  
 
18. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. 
Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988 
Sep 1;319(9):525-532.  
 
19. Hisamichi S. Screening for gastric cancer. World J Surg. 1989 Feb;13(1):31-37.  
 
20. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, 
and prevalence across five continents: defining priorities to reduce cancer 
disparities in different geographic regions of the world. J. Clin. Oncol. 2006 May 
10;24(14):2137-2150.  
 
21. Marrelli D, Stefano AD, Manzoni GD, Morgagni P, Leo AD, Roviello F. 
Prediction of Recurrence After Radical Surgery for Gastric Cancer: A Scoring 
System Obtained From a Prospective Multicenter Study. Ann Surg. 2005 
Feb;241(2):247–255.  
 
22. Lee S, Lee J, Hwang N, Kim Y, Rhee P, Kim J, et al. The role of follow-up 
endoscopy after total gastrectomy for gastric cancer. European Journal of Surgical 
Oncology. 2005 Apr;31(3):265-269.  
 
23. Weiss MM, Kuipers EJ, Postma C, Snijders AM, Siccama I, Pinkel D, et al. 
Genomic profiling of gastric cancer predicts lymph node status and survival. 
Oncogene. 2003 Mar 27;22(12):1872-1879.  
 
24. Tay ST, Leong SH, Yu K, Aggarwal A, Tan SY, Lee CH, et al. A Combined 
Comparative Genomic Hybridization and Expression Microarray Analysis of 
Gastric Cancer Reveals Novel Molecular Subtypes. Cancer Res. 2003 Jun 
15;63(12):3309-3316.  
 
25. Anderson C, Nijagal A, Kim J. Molecular markers for gastric adenocarcinoma: an 
update. Mol Diagn Ther. 2006;10(6):345-352.  
 
26. Han S, Oh D, Im S, Park SR, Lee K, Song HS, et al. Phase II study and biomarker 
analysis of cetuximab combined with modified FOLFOX6 in advanced gastric 
cancer. Br. J. Cancer. 2009 Jan 27;100(2):298-304.  
 
27. Kaminishi M, Takubo K, Mafune K. The Diversity of Gastric Carcinoma: 
Pathogenesis, Diagnosis and Therapy.  1st ed.  Springer; 2005.  
 
 91 
28. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, et al. 
Comparative genomic hybridization for molecular cytogenetic analysis of solid 
tumors. Science. 1992 Oct 30;258(5083):818-821.  
 
29. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Döhner H, et 
al. Matrix-based comparative genomic hybridization: biochips to screen for 
genomic imbalances. Genes Chromosomes Cancer. 1997 Dec;20(4):399-407.  
 
30. Shizuya H, Birren B, Kim UJ, Mancino V, Slepak T, Tachiiri Y, et al. Cloning 
and stable maintenance of 300-kilobase-pair fragments of human DNA in 
Escherichia coli using an F-factor-based vector. Proc Natl Acad Sci U S A. 1992 
Sep 15;89(18):8794–8797.  
 
31. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, 
et al. Laser capture microdissection. Science. 1996 Nov 8;274(5289):998-1001.  
 
32. Paris PL, Albertson DG, Alers JC, Andaya A, Carroll P, Fridlyand J, et al. High-
Resolution Analysis of Paraffin-Embedded and Formalin-Fixed Prostate Tumors 
Using Comparative Genomic Hybridization to Genomic Microarrays. Am J 
Pathol. 2003 Mar 1;162(3):763-770.  
 
33. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, et al. Whole 
genome scanning identifies genotypes associated with recurrence and metastasis 
in prostate tumors. Hum. Mol. Genet. 2004 Jul 1;13(13):1303-1313.  
 
34. Lage JM, Leamon JH, Pejovic T, Hamann S, Lacey M, Dillon D, et al. Whole 
Genome Analysis of Genetic Alterations in Small DNA Samples Using 
Hyperbranched Strand Displacement Amplification and Array–CGH. Genome 
Research. 2003 Feb 1;13(2):294-307.  
 
35. Telenius H, Carter NP, Bebb CE, Nordenskjo¨ld M, Ponder BA, Tunnacliffe A. 
Degenerate oligonucleotide-primed PCR: General amplification of target DNA by 
a single degenerate primer. Genomics. 1992 Jul;13(3):718-725.  
 
36. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmüller G. 
Comparative genomic hybridization, loss of heterozygosity, and DNA sequence 
analysis of single cells. Proceedings of the National Academy of Sciences of the 
United States of America. 1999 Apr 13;96(8):4494-4499.  
 
37. Zhang L, Cui X, Schmitt K, Hubert R, Navidi W, Arnheim N. Whole genome 
amplification from a single cell: implications for genetic analysis. Proc. Natl. 
Acad. Sci. U.S.A. 1992 Jul 1;89(13):5847-5851.  
 
38. Lee CIP, Leong SH, Png AEH, Choo KW, Syn C, Lim DTH, et al. An isothermal 
primer extension method for whole genome amplification of fresh and degraded 
DNA: applications in comparative genomic hybridization, genotyping and 
mutation screening. Nat. Protocols. 2006 Dec;1(5):2185-2194.  
 
39. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, et al. 
Assembly of microarrays for genome-wide measurement of DNA copy number. 
 92 
Nat Genet. 2001 Nov;29(3):263-264.  
 
40. Jain AN, Tokuyasu TA, Snijders AM, Segraves R, Albertson DG, Pinkel D. Fully 
Automatic Quantification of Microarray Image Data. Genome Res. 2002 
Feb;12(2):325–332.  
 
41. Srinivasan M, Sedmak D, Jewell S. Effect of Fixatives and Tissue Processing on 
the Content and Integrity of Nucleic Acids. Am J Pathol. 2002 Dec;161(6):1961–
1971.  
 
42. Delfour C, Roger P, Bret C, Berthe M, Rochaix P, Kalfa N, et al. RCL2, a New 
Fixative, Preserves Morphology and Nucleic Acid Integrity in Paraffin-Embedded 
Breast Carcinoma and Microdissected Breast Tumor Cells. J Mol Diagn. 2006 
May;8(2):157–169.  
 
43. Douglas EJ, Fiegler H, Rowan A, Halford S, Bicknell DC, Bodmer W, et al. Array 
comparative genomic hybridization analysis of colorectal cancer cell lines and 
primary carcinomas.  AACR; 2004.  
 
44. Kolosionek E, Savai R, Ghofrani HA, Weissmann N, Guenther A, Grimminger F, 
et al. Expression and Activity of Phosphodiesterase Isoforms during Epithelial 
Mesenchymal Transition: The Role of Phosphodiesterase 4. Mol. Biol. Cell. 2009 
Nov 15;20(22):4751-4765.  
 
45. Falchetti M, Saieva C, Lupi R, Masala G, Rizzolo P, Zanna I, et al. Gastric cancer 
with high-level microsatellite instability: target gene mutations, clinicopathologic 
features, and long-term survival. Hum. Pathol. 2008 Jun;39(6):925-932.  
 
46. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than 
breast or ovarian. MedGenMed. 2005;7(2):60.  
 
47. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline 
mutations in BRCA1 or BRCA2: a review of the literature. J. Clin. Oncol. 2004 
Feb 15;22(4):735-742.  
 
48. Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubiński J. BRCA2 gene mutations 
in families with aggregations of breast and stomach cancers. Br. J. Cancer. 2002 
Oct 7;87(8):888-891.  
 
49. Takahata M, Inoue Y, Tsuda H, Imoto I, Koinuma D, Hayashi M, et al. SKI and 
MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric 
cancer cells. J. Biol. Chem. 2009 Jan 30;284(5):3334-3344.  
 
50. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified 
squamous epithelium; clinical implications of multicentric origin. Cancer. 1953 
Sep;6(5):963-968.  
 
51. Bernstein C, Bernstein H, Payne CM, Dvorak K, Garewal H. Field defects in 




52. Chen L, Hao C, Chiu YSY, Wong P, Melnick JS, Brotman M, et al. Alteration of 
gene expression in normal-appearing colon mucosa of APC(min) mice and human 
cancer patients. Cancer Res. 2004 May 15;64(10):3694-3700.  
 
53. Hao C, Moore DH, Chiu YSY, Wong P, Bennington JL, Smith AP, et al. Altered 
gene expression in normal colonic mucosa of individuals with polyps of the colon. 
Dis. Colon Rectum. 2005 Dec;48(12):2329-2335.  
 
54. Brabender J, Marjoram P, Lord RV, Metzger R, Salonga D, Vallbohmer D, et al. 
The Molecular Signature of Normal Squamous Esophageal Epithelium Identifies 
the Presence of a Field Effect and Can Discriminate between Patients with 
Barrett's Esophagus and Patients with Barrett's-Associated Adenocarcinoma. 
Cancer Epidemiol Biomarkers Prev. 2005 Sep 1;14(9):2113-2117.  
 
55. Strong MS, Incze J, Vaughan CW. Field cancerization in the aerodigestive tract--
its etiology, manifestation, and significance. J Otolaryngol. 1984 Feb;13(1):1-6.  
 
56. Steiling K, Ryan J, Brody JS, Spira A. The field of tissue injury in the lung and 
airway. Cancer Prev Res (Phila Pa). 2008 Nov;1(6):396-403.  
 
57. Polley AC, Mulholland F, Pin C, Williams EA, Bradburn DM, Mills SJ, et al. 
Proteomic analysis reveals field-wide changes in protein expression in the 
morphologically normal mucosa of patients with colorectal neoplasia. Cancer 
Research. 2006;66(13):6553.  
 
58. Subramanian H, Roy HK, Pradhan P, Goldberg MJ, Muldoon J, Brand RE, et al. 
Nanoscale Cellular Changes in Field Carcinogenesis Detected by Partial Wave 
Spectroscopy. Cancer Res. 2009 Jul 1;69(13):5357-5363.  
 
59. Subramanian H, Pradhan P, Liu Y, Capoglu IR, Li X, Rogers JD, et al. Optical 
methodology for detecting histologically unapparent nanoscale consequences of 
genetic alterations in biological cells. Proceedings of the National Academy of 
Sciences. 2008 Dec 23;105(51):20118-20123.  
 
60. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J. 
Differences in gene expression in prostate cancer, normal appearing prostate 
tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC 
Cancer. 2005;5:45.  
 
61. Ellsworth DL, Ellsworth RE, Liebman MN, Hooke JA, Shriver CD. Genomic 
instability in histologically normal breast tissues: implications for carcinogenesis. 
Lancet Oncol. 2004 Dec;5(12):753-758.  
 
62. Lakhani SR, Chaggar R, Davies S, Jones C, Collins N, Odel C, et al. Genetic 
alterations in 'normal' luminal and myoepithelial cells of the breast. J. Pathol. 1999 
Dec;189(4):496-503.  
 
63. Sud R, Wells D, Talbot IC, Delhanty JD. Genetic alterations in gastric cancers 
from British patients. Cancer Genet. Cytogenet. 2001 Apr 15;126(2):111-119.  
 94 
 
64. Nakase Y, Sakakura C, Miyagawa K, Kin S, Fukuda K, Yanagisawa A, et al. 
Frequent loss of RUNX3 gene expression in remnant stomach cancer and adjacent 
mucosa with special reference to topography. Br. J. Cancer. 2005 Feb 
14;92(3):562-569.  
 
65. Nishimura T. Total number of genome alterations in sporadic gastrointestinal 
cancer inferred from pooled analyses in the literature. Tumour Biol. 
2008;29(6):343-350.  
 
66. Wu C, Kao H, Li AF, Chi C, Lin W. Protein tyrosine-phosphatase expression 
profiling in gastric cancer tissues. Cancer Lett. 2006 Oct 8;242(1):95-103.  
 
67. Buffart TE, Carvalho B, Hopmans E, Brehm V, Kranenbarg EK, Schaaij-Visser 
TBM, et al. Gastric cancers in young and elderly patients show different genomic 
profiles. J. Pathol. 2007 Jan;211(1):45-51.  
 
68. Zhang YJ, Fang JY. Molecular staging of gastric cancer. J. Gastroenterol. 
Hepatol. 2008 Jun;23(6):856-860.  
 
69. Mc Sherry EA, Mc Goldrick A, Kay EW, Hopkins AM, Gallagher WM, Dervan 
PA. Formalin-fixed paraffin-embedded clinical tissues show spurious copy 
number changes in array-CGH profiles. Clin. Genet. 2007 Nov;72(5):441-447.  
 
70. Johnson NA, Hamoudi RA, Ichimura K, Liu L, Pearson DM, Collins VP, et al. 
Application of array CGH on archival formalin-fixed paraffin-embedded tissues 
including small numbers of microdissected cells. Lab. Invest. 2006 Sep;86(9):968-
978.  
 
71. Ghazani AA, Arneson NCR, Warren K, Done SJ. Limited tissue fixation times 
and whole genomic amplification do not impact array CGH profiles. J. Clin. 
Pathol. 2006 Mar;59(3):311-315.  
 
72. Jacobs S, Thompson ER, Nannya Y, Yamamoto G, Pillai R, Ogawa S, et al. 
Genome-wide, high-resolution detection of copy number, loss of heterozygosity, 
and genotypes from formalin-fixed, paraffin-embedded tumor tissue using 
microarrays. Cancer Res. 2007 Mar 15;67(6):2544-2551.  
 
73. Buffart TE, Tijssen M, Krugers T, Carvalho B, Smeets SJ, Brakenhoff RH, et al. 
DNA quality assessment for array CGH by isothermal whole genome 
amplification. Cell. Oncol. 2007;29(4):351-359.  
 
74. Vollmer E, Galle J, Lang DS, Loeschke S, Schultz H, Goldmann T. The HOPE 
technique opens up a multitude of new possibilities in pathology. Rom J Morphol 
Embryol. 2006;47(1):15-19.  
 
75. Stanta G, Mucelli SP, Petrera F, Bonin S, Bussolati G. A novel fixative improves 
opportunities of nucleic acids and proteomic analysis in human archive's tissues. 




Appendix 1: Protocol of DNA extraction from FFPE tissue 
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Appendix 2: Protocol of Random Primer Labeling 
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Appendix 3: Protocol of BAC array hybridization 
 
 
 
 
